Latest Breaking News On - Ping cao - Page 4 : vimarsana.com
BridGene Biosciences to Present at the Virtual H C Wainwright 23rd Annual Global Investment Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BridGene Biosciences to Present at the Virtual H C Wainwright 23rd Annual Global Investment Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
A Queensland man who dissolved his wife s body in a wheelie-bin of acid after murdering her is applying for parole after serving less than 10 years in jail.
BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company s Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
News provided by
Share this article
Share this article
SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
BridGene plans to use proceeds from the Series A financing to expand the company s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.
Published: May 05, 2021 By Mark Terry
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
Esker Launches with $70 Million Series A
San Francisco-based Esker Therapeutics, a Foresite Labs-incubated company,
launched with a $70 million Series A financing. The round was led by Foresite Capital. The company focuses on autoimmune diseases and so-called precision therapies that target patients most likely to benefit from them.
The company’s precision analytics platform is powered by Foresite Labs. The technology platform is made up of high-quality curated genetic, clinical and medical record data, a systems immunology approach for prospective data collections and tools for building patient registries. Its lead pipeline product is ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1, initially in development for psoriasis. It is currently in a Phase
vimarsana © 2020. All Rights Reserved.